2015.06.03

 

 

Cancer °ü·Ã ½ÅÁ¦Ç°

Recombinant Human IL-35 Ãâ½Ã!

IL-35´Â regulatory T cell ¹× B cell¿¡¼­ ºÐºñµÇ´Â cytokineÀÌ¸ç ´Ù¾çÇÑ cancer model¿¡¼­ ³·Àº activity¸¦ º¸ÀÌ´Â °ÍÀ¸·Î È®ÀεƽÀ´Ï´Ù.

R&D recombinant human IL-35´Â

- 80% ÀÌ»óÀÇ ³ôÀº purity

- 0.1EU/ug ÀÌÇÏÀÇ ³·Àº endotoxin leve

- 20ng/mlÀÇ °íÈ¿À² activity¸¦ º¸ÀÔ´Ï´Ù.


Brachyury Antibody for ICC

Brachyury´Â transcription factor·Î½á ´Ù¾çÇÑ cancer model¿¡¼­ upregulation µÈ´Ù°í ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.

Cancer °ü·Ã ÃֽŠ³í¹®

ErbB2+ breast cancer¿¡¼­ÀÇ ¾àÀç³»¼º ¹æÁö

ErbB2¸¦ targetÀ¸·Î ÇÑ Ç×¾ÏÄ¡·á Áß Á¾Á¾ ¾àÀç³»¼ºÀÌ »ý±â±âµµ Çϴµ¥, BET bromodomain inhibitorÀÎ JQ1ÀÌ ErbB2/ErbB3 signal reprogramminÀ» ¾ïÁ¦, ErbB2 target Ä¡·á È¿°ú¸¦ ÁõÁø½ÃŲ´Ù´Â ³í¹®ÀÌ ¹ßÇ¥µÆ½À´Ï´Ù.

>>> Cancer °ü·Ã activator/inhibitor È®ÀÎÇϱâ


PLZF¿Í CRPC developmentÀÇ »ó°ü°ü°è

ÃÖ±Ù PLZF°¡ knockdownµÇ¸é ¾Ï Çü¼ºÀÌ È°¹ßÇØÁø´Ù´Â ¿¬±¸ °á°ú°¡ ¹ßÇ¥µÆ½À´Ï´Ù. ¶ÇÇÑ, castration-resistant prostate cancer (CRPC)°¡ »À·Î ÀüÀÌµÉ ¶§ PLZFÀÇ ¹ßÇöÀÌ Å©°Ô ÁÙ¾ú´Ù´Â ³»¿ëµµ ÇÔ²² Æ÷ÇԵƽÀ´Ï´Ù.


°ü·Ã Á¦Ç°


R&D systems 25ug ¼Ò¿ë·® antibody!

- º»°ÝÀûÀÎ ½ÇÇè¿¡ ¾Õ¼­ pilot test¸¦ ¿øÇϽóª¿ä?

- ½ÇÇè ¾çÀÌ ¸¹Áö ¾Ê¾Æ¼­ ÀûÀº ¾çÀÇ antibody¸¸ ÇÊ¿ä·Î ÇϽóª¿ä?

- R&D systems Àü Á¦Ç° 25ug ¼Ò¿ë·® antibody°¡ Ãâ½Ã µÆ½À´Ï´Ù!


Luminex ºÐ¼®¼­ºñ½º cancer panel

- Cancer °ü·Ã ¸ðµç markerµéÀ» ÇѲ¨¹ø¿¡ Á¤·®Çϼ¼¿ä!

- Àåºñ°¡ ¾ø¾îµµ °ÆÁ¤ÇÏÁö ¸¶¼¼¿ä~ ¿õºñ¸ÞµðÅØ ºÐ¼®¼­ºñ½º°¡ ÀÖÀ¸´Ï±î¿ä!


Proteome Profiler Antibody Array

- Cancer signaling °ü·Ã markerµéÀ» ÇѲ¨¹ø¿¡ screening Çϼ¼¿ä!

- Western blot°ú °ÅÀÇ µ¿ÀÏÇÑ ½ÇÇè ¹æ¹ý!

- Most referenced antibody array!

 

Á¦Ç° »ó´ã : Çмú¸¶ÄÉÆÃÆÀ ÇѼҿµ (techserv@woongbee.com / 031-776-3300 ³»¼±122)